Table 2:
Long-term treatment outcomes for EoE patients responsive to PPI treatment with endoscopic follow-up (n = 50)
| Baseline (no PPI) | Initial PPI response | Final endoscopy | p* | |
|---|---|---|---|---|
| Daily total PPI (mean mg ± SD) | -- | 49 ± 16 | 40 ± 19 | 0.004 |
| PPI dose category (n, %)† | ||||
| Single/standard | -- | 3 (6) | 21 (41) | < 0.001 |
| Double | -- | 40 (80) | 26 (52) | |
| Quadruple | -- | 7 (14) | 3 (6) | |
| Endoscopic findings (n, %) | ||||
| Rings | 32 (64) | 26 (52) | 19 (38) | 0.06 |
| Stricture | 18 (36) | 22 (44) | 23 (46) | 0.73 |
| Narrowing | 6 (12) | 4 (8) | 3 (6) | 0.56 |
| Furrows | 31 (62) | 21 (42) | 15 (30) | 0.11 |
| Exudates | 21 (42) | 6 (12) | 9 (18) | 0.41 |
| Edema | 17 (34) | 9 (18) | 11 (22) | 0.59 |
| Dilation | 22 (44) | 19 (38) | 23 (46) | 0.32 |
| Total EREFS score | 4.2 ± 1.5 | 1.8 ± 1.4 | 1.9 ± 1.7 | 0.62 |
| Peak eosinophil count | ||||
| Mean eos/hpf ± SD | 65.9 ± 50.7 | 5.2 ± 4.6 | 22.0 ± 33.0 | < 0.001 |
| Median eos/hpf (IQR) | 50 (35–75) | 5 (2–8)) | 8 (0–34) | 0.005 |
| Histologic response (n, %) | ||||
| <15 eos/hpf | -- | 50 (100) | 30 (60) | < 0.001 |
| <5 eos/hpf | -- | 23 (46) | 22 (44) | 0.82 |
| Symptom response (n, %) | 50 (100) | 32 (64) | < 0.001 |
*
Comparison between initial PPI response endoscopy and final endoscopy; means compared with paired t-tests, proportions compared with McNemar’s test, medians compared with Wilcoxon Signed-rank
†
Categorization based one standard doses as follows: omeprazole 20 mg, pantoprazole 40mg, esomeprazole 20 mg, lansoprazole 30 mg, with double and quadruple calculated accordingly; no patients received rabeprazole